Annotation Detail
Information
- Associated Genes
- CTLA4
- Associated Variants
- CTLA4 UNKNOWN
- Source Database
- MMMP
- Description
- Phase II randomized dose ranging study (metastatic setting). Ipilimumab elicited a dose-dependent effect on efficacy (P for trend: 0.0015) and safety measures in pretreated patients with advanced melanoma, lending support to further studies at a dose of 10 mg/kg. The best overall response rate was 11.1%
- MMMP State
- uncharacterized
- MMMP Molecule
- CTLA4
- MMMP Relationship
- sensitivity to
- MMMP Drug
- Ipilimumab
- MMMP Drug Alias
- CTLA4 antibody (antagonist)
- MMMP Model
- 5
- MMMP Reference
- Wolchok JD, Lancet Oncol 2010, 11:155-64
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ipilimumab | Sensitivity | true |